AbbVie (NYSE: ABBV ) , which was spun out of health care stalwart Abbott Laboratories (NYSE: ABT ) at the start of 2013, has beaten the market -- and its former parent company -- by leaps and bounds this year. It reported solid second-quarter results, largely fueled by 16% year-over-year sales growth of its top-selling autoimmune disease drug, Humira, but are there any threats to AbbVie's most important product? In the following video, from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso review the highlights from AbbVie's second-quarter results, discuss the company's dependence on its high-flying blockbuster drug, and explain potential competitive threats to Humira, such as Pfizer's drug Xeljanz.
AbbVie may be beating the market this year, but Motley Fool co-founder David Gardner, founder of the No. 1 growth stock newsletter in the world, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.